Breakthrough Mitochondrial Science A Source for Novel Therapeutics

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases.

Topline Data & Q2 2021 Investor Presentation

Topline Data & Q2 2021 Investor Presentation Audio Replay

Corporate Presentation

Harnessing the Therapeutic Potential of Mitochondrial DNA

Our company is a first mover and leader in exploring the mitochondrial genome for therapeutically relevant peptides that have the potential to be developed into transformative and commercially successful drugs. These peptides have been conserved by evolutionary biology due to their important roles in sensing and regulating critical biological functions, far beyond the energy production most frequently associated with mitochondria. Our team has discovered more than 100 mitochondrial derived peptides (MDPs) and generated over 1,000 analogs.

Our Science

Proprietary Platform Technology

CohBar has developed a proprietary mitochondria based therapeutic (MBT) platform technology, using cell-based assays and animal models of disease, to rapidly identify naturally occurring MDPs with promising biological activity. Once identified, we deploy optimization techniques to improve the drug-like properties of our MBT candidates, enabling us to match the most biologically promising peptides to disease indications that have substantial unmet medical needs. Our ongoing research and development activities focus on discovery and development of novel improved MDP analogs that have the greatest therapeutic and commercial potential. Recent data continues to strengthen the evidence supporting the breadth of biological effects and therapeutic potential of our novel analogs of mitochondrial peptides.

Our Platform

Pipeline of Clinical and Preclinical Programs

We currently have one clinical program with a unique mechanism of action targeting nonalcoholic steatohepatitis (NASH) and obesity and four preclinical programs including an antifibrotic program targeting idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, an apelin agonist for acute respiratory distress syndrome (ARDS), including COVID-19 associated ARDS, a CXCR4 antagonist for potential use in oncology, stem cell mobilization and/or genetic diseases, and an immuno-oncology program.

Our Pipeline

Stock Information

CohBar, Inc.


Nasdaq: CWBR




Day Range

52 Week Range

Email Sign Up